Wedbush Upgrades Fate Therapeutics to Outperform, Raises Price Target to $7

Benzinga · 10/27 12:40
Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outperform and raises the price target from $5 to $7.